Shifting Paradigms: In Glaucoma and Geographic Atrophy

This content is independent editorial sponsored by Astellas. Astellas had no input in the development of this content.

In this Feature

The New Era of GA Care

Nathan Radcliffe, MD; John Kitchens, MD; and Deborah Ristvedt, DO

Geographic Atrophy: Past to Present

Nathan Radcliffe, MD; John Kitchens, MD; and Deborah Ristvedt, DO

Shifting Paradigms: In Glaucoma and GA

Nathan Radcliffe, MD; John Kitchens, MD; and Deborah Ristvedt, DO

Monitoring Geographic Atrophy

Nathan Radcliffe, MD; John Kitchens, MD; and Deborah Ristvedt, DO

GA Case Review

Nathan Radcliffe, MD; John Kitchens, MD; and Deborah Ristvedt, DO

Interactive Supplements

Shifting Paradigms in Glaucoma and GA

View Resource

Listen as a Podcast

GT: The Podcast

All episodes of this series are also available as podcasts in the GT: The Podcast podcast feed.

Listen Now

About This Editorial Feature

With the introduction of therapies like Izervay (Iveric Bio) and Syfovre (Apellis), experts agree that 2023 was an important year in advancements for geographic atrophy (GA). Now that providers have tools to treat this disease, it is time to adopt a new management approach as well. Here, Nathan Radcliffe, MD; Deborah Ristvedt, DO; and John Kitchens, MD, discuss an updated approach to tackling GA and reflect on the similarly shifting paradigms in GA and glaucoma care.

Editorial Feature:

Shifting Paradigms: In Glaucoma and Geographic Atrophy

In this Feature

Interactive Supplements

Listen as a Podcast